Format

Send to

Choose Destination
J Neural Transm (Vienna). 2017 Jan;124(1):113-119. doi: 10.1007/s00702-016-1630-6. Epub 2016 Oct 7.

A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease.

Author information

1
Neurology Department, Nyírő Gyula Hospital-National Institute of Psychiatry and Addictions, Budapest, Hungary.
2
National Institute for Medical Rehabilitation, Budapest, Hungary.
3
Department of Neurology, Semmelweis University, Budapest, Hungary.
4
Department of Behavioral Sciences, Faculty of Medicine, University of Szeged, Szeged, Hungary.
5
Neurology Department, Nyírő Gyula Hospital-National Institute of Psychiatry and Addictions, Budapest, Hungary. szkeri@cogsci.bme.hu.
6
Department of Cognitive Science, Budapest University of Technology and Economics, Egry str. 1, Budapest, 1111, Hungary. szkeri@cogsci.bme.hu.
7
Department of Physiology, Faculty of Medicine, University of Szeged, Szeged, Hungary. szkeri@cogsci.bme.hu.

Abstract

Despite the well-known neuropsychiatric side effects of dopaminergic medications, the possible subjective psychotomimetic effects of a single dose of L-DOPA in newly diagnosed, drug-naïve patients with Parkinson's disease (PD) are not known. To investigate this question, we used a visual search task for latent inhibition (LI), the Community Assessment of Psychic Experiences (CAPE) scale, and visual analog scales for psychotomimetic effects (perception, relaxation, and dysphoria) in 28 de novo PD patients before (off) and after (on) the adminstration of L-DOPA and in 25 matched healthy control individuals. Results revealed increased LI in PD-off and decreased LI in PD-on relative to the control subjects. After the administration of L-DOPA, we observed a significant decline in LI in PD. L-DOPA also enhanced perceptual experiences (changes in subjective feelings in thinking, time perception, and mental "highness"). Greater reduction in LI was associated with enhanced perceptual experiences. These results suggest that a single dose of L-DOPA has a significant psychotomimetic effect, which is associated with decreased LI, a behavioral marker of psychosis-like experiences.

KEYWORDS:

L-DOPA; Latent inhibition; Parkinson’s disease; Psychosis; Psychotomimetic effects

PMID:
27718013
DOI:
10.1007/s00702-016-1630-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center